# HealX

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/healx

- Industry: Biotechnology
- Headquarters: Cambridge, UK
- Website: www.healx.io
- Total disclosed funding: $114M
- Latest round: Series C (Jul 2, 2024)
- Investors on record: 10

## About

HealX Ltd., based in the UK, specializes in AI-driven drug discovery targeting rare diseases, leveraging advanced technologies to identify and develop innovative therapies to improve patient outcomes.Founded in 2014 and headquartered in Cambridge, UK, HealX Ltd. focuses on drug discovery for rare diseases. The company has undergone a strategic pivot towards utilizing artificial intelligence in its operations. In July 2025, HealX Ltd. raised USD 2 million in venture funding from SCI Ventures. The founders, David Brown, Dylan OLY, and Tim Guilliams, have experience in the biotech sector, with Tim Guilliams currently serving as CEO.HealX specializes in AI-driven drug discovery, targeting over 10,000 rare diseases affecting around 300 million people globally who lack effective treatments. The company offers a comprehensive drug development platform that facilitates the identification of potential drug-disease relationships, expediting the transition of therapies from prediction to clinical application. HealX's clientele includes pharmaceutical companies and research organizations focused on rare disease treatments, primarily serving markets in North America, Europe, and parts of Asia.In 2023, HealX reported zero revenue and an EBITDA of USD -21,727,815. The company's revenue is primarily generated through strategic partnerships with pharmaceutical firms and research institutions, facilitating co-development and commercialization of drug candidates. These partnerships typically involve B2B agreements involving milestone payments or royalties, aligning with industry standards for rare disease therapies. The company will use the July 2025 funding to accelerate the development of AI-powered therapeutics for neurotrauma.

## Funding rounds

- Series C, Jul 2, 2024, $47M — Balderton Capital, Atomico, b2venture, Global Brain, O2h Ventures, VU Venture Partners, R42, Ayana Capital
- Series B, Jul 23, 2019, $55M — Amadeus Capital Partners, Intel Capital, Balderton Capital, Atomico, b2venture, Global Brain
- Series A, Jun 18, 2018, $9.3M — Amadeus Capital Partners, Balderton Capital
- Series A, Jul 22, 2016, $2M — Amadeus Capital Partners

## Investors

- Amadeus Capital Partners (https://capitalatlas.ai/funds/amadeus-capital-partners) — Series A, Series B
- Balderton Capital (https://capitalatlas.ai/funds/balderton-capital) — Series A, Series B, Series C
- Intel Capital (https://capitalatlas.ai/funds/intel-capital) — Series B
- Atomico (https://capitalatlas.ai/funds/atomico) — Series B, Series C
- b2venture (https://capitalatlas.ai/funds/b2venture) — Series B, Series C
- Global Brain (https://capitalatlas.ai/funds/global-brain) — Series B, Series C
- O2h Ventures (https://capitalatlas.ai/funds/o2h-ventures) — Series C
- VU Venture Partners (https://capitalatlas.ai/funds/vu-venture-partners) — Series C
- R42 (https://capitalatlas.ai/funds/r42) — Series C
- Ayana Capital (https://capitalatlas.ai/funds/ayana-capital) — Series C